Five different strains of Enterobacteriaceae were isolated from two patients hospitalized in 2
Introduction 1 2
Carbapenems are the most active molecule in β-lactams with 98 % of worldwide 3 susceptibility among Enterobacteriaceae (24). However, a growing number of 4 carbapenemase-producing strains have been identified since the beginning of the 90s. They 5 displayed variable in vitro levels of resistance to carbapenems, including susceptibility (24), 6 but were clinically resistant to these molecules (35). The possible low level of resistance 7 makes reliable detection of such strains difficult (35). 8
The geographical distribution of these strains differs: those producing class A KPC-type 9 carbapenemase have been more frequently observed in the United States and in Israel whereas 10 those producing VIM-and IMP-type class B β-lactamases are generally encountered in Asia 11 and in the north of the Mediterranean basin (24). Among these enzymes metallo -12 carbapenemases are especially worrying because they virtually hydrolyze all classes of β- ATAGTTTAGCGGCCGCCCTACTCGGCGACTGAGCGATT-3' were used to amplify and 8 sequence the bla VIM gene. Direct sequencing was performed on PCR products, which were 9 obtained from the five clinical strains, the transconjugant E. coli C600 and the different 10 recombinant E. coli. These PCR products were sequenced by dideoxy chain termination on 11 both strands with an Applied Biosystems sequencer (ABI 377) (29). Primer INT/5CS 12 targeting the 5' conserved sequence of class 1 integron previously described by Riccio et al.
13
(25) (table 1) was used with VIM-1B NotI to amplify and sequence a part of the bla VIM 14 genetic environnement. The nucleotide and deduced protein sequences were analysed using 15 software available at the website of the National Center of Biotechnology Information 16 (http://www.ncbi.nlm.nih.gov). The ClustalW program (http://infobiogen.fr) was used for the 17 alignment of amino acid sequences (32) . Over-production and purification of β β β β-lactamases. VIM-19-producing E. coli BL21 (DE3) 5 clone was used to overproduce the VIM-19 β-lactamase, as previously described (6). Bacteria 6 were disrupted by sonication. The supernatant was loaded onto a Q Sepharose column (10 7 mL; Amersham Pharmacia Biotech., Orsay, France) equilibrated with 20 mM Tris-HCl (pH 8 7.4). The bound proteins were eluted with a linear NaCl gradient (0 to 500 mM). The β-9 lactamase-containing elution peak was loaded onto a Superose 12 (Amersham Pharmacia 10
Biotech.) and eluted with the buffer 5 mM Tris-HCl 100 mM NaCl (pH 7.4). The β-11 lactamase-containing elution peak was dialyzed against NaCl 100 mM, concentrated and 12 and P. stuartii 6858 were isolated in May 2008 from two different urinary samples of this 7 second patient. P. stuartii 6858 was isolated from the two samples, whereas K. pneumoniae 8 2878 and 6828 were only isolated from the first and second sample respectively. She was 9 treated with cefotaxime and died from a pulmonary embolism. 10
Both patients had been previously treated with different broad spectrum β-lactams, the first 11 with cefotaxime and the second with cefotaxime, ceftazidime and imipenem. These five 12 strains were the first strains of Enterobacteriaceae intermediate or resistant to carbapanems 13 isolated in this hospital. 14 All the five strains were intermediate or resistant to all β-lactams including carbapenems 15 (Table 1) . They were resistant to sulfonamides, trimethoprim, tetracycline, and 16 chloramphenicol They were intermediate or resistant to kanamycin, tobramycin, netilmicin, 17 amikacin and gentamicin. They were also susceptible to all quinolones and to fosfomycin. 18
The two E. coli and the two K. pneumoniae strains presented different ERIC2-PCR patterns 19 confirming they were not clonally related (data not shown). EDTA-combined disk method 20 suggested the production of a metallo-β-lactamase by the five strains. that they all harbored a bla gene encoding a VIM-type carbapenemase, and a bla gene 1 encoding a CMY-type cephalosporinase corresponding to the enzyme of pI 9. Partial 2 sequencing of the bla CMY genes showed that it encoded for a CMY-4-like enzyme. The two E. 3 coli strains 138 and 2603 also presented a bla TEM , which was identified as bla TEM-1 . No CTX-4 M-type enzyme was detected in any of these strains unlike in the Tunisian VIM-4-producing 5 strains (14) . 6
The five clinical strains harbored the same novel bla VIM gene, designated bla . This gene 7 differed from bla VIM-4 by only one substitution at position 1034 from A to C (numbering 8 according to the sequence AM181293 (14)) which led to the substitution Asn215Lys 9 according to the MBL scheme (11) . VIM-19 was therefore a new VIM enzyme which differed 10 from VIM-1 by two amino acid substitutions: Asn215Lys and Ser228Arg (previously 11 observed in VIM-2 and VIM-4). 1,024 to > 2,048 µg/ml). MICs of cefoxitin, cefotaxime and ceftazidime were slightly lower, 7 ranging from 32 to 512 µg/ml. Carbapenems and cefepime were more active with MICs 8 ranging from 1 to 64 µg/ml. Aztreonam was only active against E. coli DH 5 α (pBK-VIM-19), 9 which only produced VIM-19. The other strains, which also produced a CMY-4-like enzyme, 10 had MICs of aztreonam between 2 and 128 µg/ml. In presence of EDTA, the activity of the 11 different carbapenems was restored (MICs, <0.12 to 0.5 µg/ml). The MICs of ceftazidime and 12 cefotaxime decreased two-fold to eleven-fold but aztreonam MICs were not significantly 13 modified. 14 15 Kinetic constants (Table 2 ). The two steps of purification yielded approximately 1.6 mg of 16 pure enzyme per liter of culture. The specific activity of the extract against benzylpenicillin 17 was 419.6 µmol/min/mg. The level of purity was estimated > 97% by sodium dodecyl sulfate-18 polyacrylamide gel electrophoresis (SDS-PAGE) (2, 16). 19 Table 3 Finally, VIM-19 was 6-fold to 14-fold more active against imipenem than against ertapenem 4 and meropenem. As previously observed for other metallo-β-lactamases, VIM-19 had no 5 detectable activity against aztreonam. 6
In contrast with VIM-1, VIM-19 was slightly more efficient against penicillins than against 7 cephalosporins, as observed for VIM-2, because of lower Km values. Both VIM-2 and VIM-8 19 harbored an arginine residue at position 228 instead of a serine in VIM-1. The 9 crystallographic structure of VIM-2 revealed that the side chain of this residue was close to 10 one of the two Zn atoms (Zn 2) and interacted, in the oxidised form of VIM-2, with the 11 residues of the active site of VIM-2 located at positions 224 and 263 (12) . In addition, in the 12 reduced form of VIM-2, Arg228 contributed to the creation of a positively charged 13 environment for substrate binding (12) . These structural features, which are shared by VIM-2 14 and VIM-19, could be involved in the differences of hydrolysis profile observed between 15 VIM-1 and VIM-19. The role of substitution Asn215Lys of VIM-19 remained unclear but this 16 residue seemed to have less impact because its side-chain was oriented toward the solvent in 17 the structure of VIM-2. 18
Concluding remarks 1
Infections caused by metallo-β-lactamase-producing Enterobacteriaceae are currently a 2 worrying threat because the antibiotic options available are extremely limited and the 3 infections are associated with a high risk of mortality (31). We report here the first 4 documented cases of infections caused by VIM-producing Enterobacteriaceae strains in 5
Algeria. The five strains produced a novel VIM-type metallo-β-lactamase VIM-19. This 6 enzyme is closely related to VIM-4 and VIM-1 which are so far the most frequently observed 7 VIM-enzymes in Enterobacteriaceae strains (14, 22, 24) . As in a recent outbreak of VIM-4-8
producing Klebsiella pneumoniae in Tunisia (14), the bla VIM-19 was located among a class 1 9 integron on a large plasmid and was associated with a bla CMY gene. Our study confirms the 10 emergence of VIM-producing Enterobacteriaceae in northwest Africa and their dissemination 11 all around the Mediterranean basin. A large multicentric study would be necessary to assess 12 the dissemination of such strains in the different countries of the region. 13
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